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arthritis (ReA), rheumatoid arthritis (RA) and osteoarthritis, and
correlate them with the HLA-B27 haplotype in a subset of ReA
patients positive for Chlamydia trachomatis. The results did not
reveal signiﬁcant differences in cytokine levels and ratios among
the groups, although lower levels of interferon  (IFN-) in SF
were found in the HLA-B27-positive ReA patients than in the
negative ones.
The data presented are striking, but they merit comment. First,
the Quantikine ELISA kits used are not validated for use with
SF. Therefore, it is fair to ask why these kits were used to analyse
the SF.
Secondly, the lower levels of SF interleukin (IL) 10 in ReA
than in RA are at variance with other reports. In addition, how
do the authors explain the higher ratios of IFN- to IL-10
among the ReA patients? Animal models of Chlamydia
infection have shown that the clearance of the organism is
affected by the balance between IFN- and IL-10, and IL-10
gene knockout mice clear Chlamydia infection more rapidly than
normal [2–4].
We also wonder why IL-4 and IL-17 were not analysed.
Considering that the immune response to Chlamydia requires a
Th1 response, it would have been of interest to demonstrate the
adequacy or inadequacy of this response by determining the
presence of IL-4. In addition, IL-17 is relevant to joint destruction,
and its presence in the joints of ReA patients is of obvious interest
and importance [4].
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We thank Drs Cuchacovich and Espinoza for their interesting
comments.
Commercial ELISA kits, including the Quantikine kit, devel-
oped for serum or plasma measurements, have been widely used
to determine levels of cytokines in synovial ﬂuid (SF) [1]. In a
comparative study, cytokine measurements have been performed
in SF, plasma and culture supernatants with commercial ELISA
kits from seven companies (one of them being R & D Systems) and
similar ﬁndings were obtained with the three kinds of samples [2].
The lower levels of SF interleukin (IL)-10 in reactive arthritis
(ReA) patients compared with rheumatoid arthritis (RA) patients
have also been reported by other groups (spondylarthropathies,
mean 4.5U/ml vs RA, mean 84.6U/ml [3]; ReA, median 10 pg/ml
vs RA, median 30.3 pg/ml [4]; seronegative spondylarthropathies,
mean 9.2 pg/ml vs RA, mean 88.4 pg/ml [5]). In two of these
studies, where the SF levels of interferon (IFN)- were reported the
SF IFN-/IL-10 ratios were also higher in ReA [4] patients and
seronegative spondylarthropathy [5] patients.
These data are in contrast to the relative abundance of synovial
IL-10 mRNA reported by Kotake et al. [6] in patients with
Chlamydia-associated arthritis. However, our patients with
Chlamydia trachomatis ReA had a mean duration of arthritis
(1.4 months) shorter than that of the patients in this report (3
months). Thus, the discrepant results could be explained if IL-10
production was delayed in patients with ReA or if there is
regulation at the level of translation. These differences could also
be explained by differences in drug therapy.
IL-10 gene knockout mice clear Chlamydia infection more
rapidly than normal mice. However, lung infection with the mouse
pneumonitis biovar of C. trachomatis [7] probably differs from
human ReA because there are human serovars of C. trachomatis.
For instance, Perry et al. [8] showed that all human serovars of
C. trachomatis were much more sensitive to the direct inhibitory
actions of IFN- than the mouse pneumonitis strain.
The low IL-10 concentrations and high IFN-/IL-10 ratios
observed in SF from ReA patients could indicate an autoimmune
response to self heat shock protein (hsp) 60. Indeed, in mice
immunized with both mouse and C. trachomatis hsp60, lympho-
cytes proliferated strongly in response to mouse hsp60, secreted 6-
fold less IL-10 and exhibited a 12-fold increase in the IFN-/IL-10
ratio compared with mice immunized with mouse hsp60 alone [9].
These ﬁndings suggest than an increased IFN-/IL-10 ratio, as
observed in ReA patients, may contribute to the Chlamydia-
induced immunopathology.
IL-4 and IL-17 are certainly cytokines of interest but we could
not determine their levels because sufﬁcient SF was not available.
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SIR, We were pleased to read the report of Loo et al. in relation
to two cases of polyneuropathy associated with Churg–Strauss
syndrome (CSS) responding to intravenous pulse cyclophos-
phamide. The primary purpose of our original article was to raise
awareness that the presence of mononeuritis multiplex or, as in
these cases, distal motor polyneuropathy, should be regarded
as severe disease associated with signiﬁcant long-term morbidity.
In the current literature, the deﬁnition of severe disease in CSS is
ambiguous as far as peripheral nerve involvement is concerned.
While we acknowledge that CSS is associated with a better
prognosis when compared with other primary small-vessel vasculi-
tides [1–2], signiﬁcant neuropathic involvement can result in short-
and long-term disability. This may be prevented if we can treat
appropriate patients with adequate therapy to induce rapid
remission of disease and prevent relapse. Although steroid
monotherapy can sometimes achieve this, in our two cases steroid
alone was insufﬁcient to achieve complete remission. The use of
concomitant pulse cyclophosphamide therapy may also reduce the
cumulative dose of corticosteroid required to maintain remission,
thus avoiding the bone and metabolic complications of long-term
steroid therapy. We agree with Loo et al. that prospective out-
come studies that address the risk–beneﬁt ratio should be done,
especially to take account of functional outcome and quality of life
issues in patients with Churg–Strauss syndrome.
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Mononeuritis in Churg–Strauss syndrome in Asians
responding to intravenous cyclophosphamide
SIR, We read with interest the letter by Hoi and Morand on the
use of intravenous (i.v.) cyclophosphamide in the treatment of
mononeuritis associated with Churg–Strauss syndrome (CSS).
We agree with them that the presence of mononeuritis multiplex
is a serious complication of CSS and warrants more aggressive
therapy [1]. We wish to report two further cases of CSS, in Asians,
presenting with mononeuritis multiplex. Both patients responded
well to monthly pulses of i.v. cyclophosphamide with signiﬁcant
improvement of their neurological signs.
The ﬁrst patient was a 38-yr-old Indian lady with a 2-yr history
of bronchial asthma. She was treated with an inhaled 2 agonist
and inhaled corticosteroid. She presented with a 3-month history
of low-grade fever, generalized malaise and symmetrical poly-
arthralgia. She developed progressive paraesthesiae and weakness
affecting all four extremities 2 months after the onset of
constitutional symptoms.
On presentation, the patient had bilateral wrist and foot drop
and loss of pinprick sensation in a glove and stocking distribution.
There were generalized rhonchi on auscultation of her chest.
There were multiple purpuric rashes and non-healing ulcers on the
dorsum of both feet. Her investigation results are summarized in
Table 1. The diagnosis of CSS was made in accordance with the
American College of Rheumatology classiﬁcation criteria [2].
The patient was treated with i.v. methylprednisolone 1 g daily
for 3 days followed by oral prednisolone 1mg/kg daily, which was
gradually tapered. In addition, i.v. cyclophosphamide 0.75 g/m2
(to a maximum of 1 g) was given monthly for 6 months, with
subsequent oral azathioprine 2mg/kg daily. The absolute eosino-
phil count and elevated inﬂammatory markers dropped rapidly
within days. Her bronchial asthma remained well controlled. There
was no progression of her neurological deﬁcits. The vasculitic
ulcers were completely healed after 4 months of treatment. After 9
months of treatment, her right wrist extension, hand grip and right
foot dorsiﬂexion muscle power was 5/5 (compared with 3/5 on
presentation), the left wrist extension was 4/5 (2/5 on presentation)
and the left foot dorsiﬂexion was 2/5 (0/5 on presentation).
Pinprick sensation had returned to normal and paraesthesiae were
conﬁned to the tips of her ﬁngers and toes.
The second case was a 68-yr-old Chinese man who had had
chronic bronchial asthma and allergic rhinitis since childhood and
had a 10-yr history of chronic rhinosinusitis. The patient was
diagnosed as having pulmonary tuberculosis in June 2001 and
was treated with the standard four-drug regime, consisting of
streptomycin, isoniazid, rifampin and pyrazinamide with
pyridoxine supplementation. He was on low-dose prednisolone
daily for control of his bronchial asthma. The patient presented in
August 2002 with a 2-week history of progressive bilateral lower
limb weakness and paraesthesiae, low-grade fever and arthralgia.
On examination, he had complete bilateral foot drop, loss of
pinprick sensation over the sole and dorsum of both feet and
lateral aspects of both calves, consistent with the L5 and S1
dermatomes, and loss of proprioception in both feet. His
investigation results are summarized in Table 1.
CSS was diagnosed in the absence of other causes of
hypereosinophilia. The patient was treated with the same regime
as in case 1, with additional i.v. methylprednisolone 500mg on
each pulse of i.v. cyclophosphamide (0.75 g/m2, to a maximum
of 1 g). He completed 6 months of anti-tuberculous treatment
and subsequently had isoniazid and pyridoxine prophylaxis until
he ﬁnished the six i.v. cyclophosphamide pulses. The hypereosin-
ophilia and elevated inﬂammatory markers resolved within days,
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